The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond
Abstract
The protease A Disintegrin And Metalloproteinase 17 (ADAM17) plays a central role in the pathophysiology of several diseases. ADAM17 is involved in the cleavage and shedding of at least 80 known membrane‐tethered proteins, which subsequently modulate several intracellular signaling pathways, and therefore alter cell behavior. Dysregulated expression and/or activation of ADAM17 has been linked to a wide range of autoimmune and inflammatory diseases, cancer, and cardiovascular disease. In this review, we provide an overview of the current state of knowledge from preclinical models and clinical data on the diverse pathophysiological roles of ADAM17, and discuss the mechanisms underlying ADAM17‐mediated protein shedding and the potential therapeutic implications of targeting ADAM17 in these diseases.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 11, 2023
- Source ID
- 10.1111/febs.16923
Entities
People
- Brendan J. Jenkins
- Mohamed I. Saad
Organizations
- Hudson Institute of Medical Research
- Monash University
- United States Department of Defense
- University of Adelaide